A randomized, open-label, study of the impact of two doses of subcutaneous recombinant IL-2 (Proleukin) [aldesleukin] on viral burden and CD4+ cell count in patients with HIV-1 infection and CD4+ cell counts greater than or equal to 300/mm3
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Aldesleukin (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 29 Sep 2008 Actual end date (Aug 2007) added as reported by CT.gov
- 29 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
- 14 Oct 2005 New trial record.